Results 141 to 150 of about 4,368 (201)

Non-steroidal mineralocorticoid receptor antagonists in non-diabetic kidney disease: a narrative review of mechanisms and clinical advances. [PDF]

BMC Nephrol
Luo F, Hu J, Fang H, Li X, Zhu C, Bao Z.
europepmc   +1 more source

Real-world study of finerenone in patients with heart failure with preserved ejection fraction in Spain. [PDF]

BMC Cardiovasc Disord
Lamilla Álvarez A, Ripoll Martínez M, Russo Botero S, López Álvarez A, Muela Molinero A, Fácila Rubio L, García Lamigueiro C, Rodríguez Ávila EE, Fernández Rodríguez JM, Bea Granell S, García Escrivá D, Pérez Silvestre J.   +11 more
europepmc   +1 more source

Finerenone Beyond Diabetic Kidney Disease: Emerging Evidence and Potential Systemic Implications. [PDF]

J Clin Med
Almaimani M, Alamri SA.
europepmc   +1 more source

Renin-Angiotensin System (RAS) Inhibitors in High-Risk Patients With Type 2 Diabetes and Cardio-Renal Risk. [PDF]

Cureus
Ahmed MJ, Ahmad AM, Naqvi S, Ahmed K, Ahmed A, Naqvi Z.   +5 more
europepmc   +1 more source

Druggable Mendelian randomization prioritizes CDH2 and supports finerenone as a candidate therapeutic strategy for diabetic retinopathy. [PDF]

Front Pharmacol
Liu X, Zhang N, Wu S, Zhang M, Sun B, Chen L.   +5 more
europepmc   +1 more source

Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial. [PDF]

Diabetes Care
Beernink JM, Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Groop PH, Ji L, Mathieu C, Mathieu C, Rosas SE, Tuttle KR, Skyler JS, Amor AJ, Caramori ML, Fiorina P, Jongs N, Pagotto U, Setola E, Brinker M, Lawatscheck R, Russel J, Schloemer P, McGill JB, Rossing P, FINE-ONE investigators* .   +24 more
europepmc   +1 more source

Impact of the Four Pillars on Electrolyte Derangements during State-of-the-Art Therapy for Diabetic Kidney Disease. [PDF]

Electrolyte Blood Press
Yoo MJ, Lee S.
europepmc   +1 more source

Correction: Efficacy of combined sodium-glucose cotransporter 2 inhibitors and finerenone in chronic kidney disease: a systematic review and meta-analysis. [PDF]

Front Pharmacol
Wen CF, Chuang MH, Wu VC, Chen JY.
europepmc   +1 more source

Hemodynamic effects of finerenone on blood pressure and heart rate in hospitalized patients with type 2 diabetes: a real-world study. [PDF]

Front Endocrinol (Lausanne)
Wen S, Yun D, He Y, Li X, Chen L, Wang C, Zhu Y, Xu D, Liu D, Li J, Zhou L.   +10 more
europepmc   +1 more source